Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy
The Series B extension proceeds will fund Phase III trial for Cerevance’s lead CNS therapy, CVN424, in patients with Parkinson’s disease.
The Series B extension proceeds will fund Phase III trial for Cerevance’s lead CNS therapy, CVN424, in patients with Parkinson’s disease.
What's Your Reaction?
